Mosaic ImmunoEngineering Inc. (CPMV)
OTCMKTS: CPMV · Delayed Price · USD
0.313
0.00 (0.00%)
Apr 22, 2024, 3:12 PM EDT - Market closed
Company Description
Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use.
Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals.
The company was founded in 2020 and is based in Novato, California.
Mosaic ImmunoEngineering Inc.
| Country | United States |
| Founded | 1992 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | Steven W. King |
Contact Details
Address: 9114 Adams Ave., #202 Huntington Beach, California 92646 United States | |
| Phone | 657-208-0890 |
| Website | mosaicie.com |
Stock Details
| Ticker Symbol | CPMV |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000836564 |
| CUSIP Number | 61945M101 |
| ISIN Number | US61945M1018 |
| Employer ID | 84-1070278 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Steven W. King | Chairman of the Board, President and Chief Executive Officer |
| Paul J. Lytle CPA | Executive Vice President, Chief Financial Officer, Secretary and Director |
| Jay Carlson | Senior Manager of Investor Relations |
| Joseph S. Shan M.P.H. | Head of Clinical Operations |
| Dr. Marvin R. Garovoy M.D. | Head of Medical Immuno-Oncology |
| Cyril Empig Ph.D. | Head of Vaccine Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 19, 2024 | 8-K | Current Report |
| Apr 15, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
| Mar 28, 2024 | 8-K | Current Report |
| Nov 2, 2023 | 10-Q | Quarterly Report |
| Aug 3, 2023 | 10-Q | Quarterly Report |
| Jun 26, 2023 | 8-K | Current Report |
| May 12, 2023 | 10-Q | Quarterly Report |
| May 3, 2023 | 8-K | Current Report |
| Mar 2, 2023 | 10-K | Annual Report |